On November 29, IQVIA Holdings’ (IQV) stock price closed at $124.95, which is ~6% growth from its close of $117.73 on November 23. IQVIA’s stock price grew from $97.90 at the close of the market on December 29, 2017, to $124.95 at the close of the market on November 23, which reflects ~28% YTD (year-to-date) growth.
On November 29, IQVIA Holdings’ stock price closed at $124.95, which is ~36% growth from its 52-week low of $91.57 on May 16. On October 22, IQVIA hit its 52-week high of $135.45.
Financials in a nutshell
IQVIA generated net revenues of $7.7 billion over the first nine months of 2018—compared to $7.2 billion during the same period in 2017, which is ~8% YoY (year-over-year) growth. The company’s revenue growth could boost the Generic Drugs ETF’s (GNRX) shares prices. IQVIA accounts for ~7.40% of GNRX’s total portfolio holdings.
IQVIA’s net income and diluted EPS during the first nine months of 2018 amounted to $190.0 million and $0.91, respectively—compared to $250.0 million and $1.11 during the same period in 2017.
Guidance for 2018
IQVIA expects the net revenues for 2018 to be $10.335 million–$10.385 million. The company expects its adjusted EBITDA to be $2.195 million–$2.225 million in 2018.
IQVIA expects its adjusted diluted EPS to be $5.45 to $5.55.
Among the 21 analysts tracking IQVIA Holdings in November, seven recommended a “strong buy,” nine recommended a “buy,” and five recommended a “hold.”
On November 30, IQVIA had a consensus 12-month target price of $140.06, which represents an ~12.09% return on investment over the next 12 months.